TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16393758

Group type: EXPERIMENTAL
Intervention: Semantic dementia (SDL)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Alzheimer's disease (AD)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Semantic dementia (SDR)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Semantic dementia (SD)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard verbal episodic memory tests
Number of subjects: 3

Group type: COMPARATOR
Intervention: Visual memory tests
Number of subjects: 3
Study: 12669250

Group type: EXPERIMENTAL
Intervention: Biochemotherapy (cisplatinum 30 mg/m2 days 1-3, DTIC 250 mg/m2 days 1-3 i.v., Interferon-alpha2b 10 MIU s.c. 3 days a week, on a 28-day cycle)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated patients (14 patients total)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biochemotherapy (cisplatinum, DTIC, Interferon-alpha2b)
Number of subjects: 10
Study: 10839336

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Right unilateral ECT (RUL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patients post-ECT
Number of subjects: 55
Study: 8979185

Group type: EXPERIMENTAL
Intervention: Single-lumen umbilical catheter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-lumen umbilical catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: No umbilical catheter; peripheral intravenous lines only (control group)
Number of subjects: 0
Study: 1485658

Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6427714

Group type: EXPERIMENTAL
Intervention: 100 micrograms mestranol plus 0.5 mg ethynodiol diacetate (100 M + 0.5 ED)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 100 micrograms mestranol plus 1.0 mg ethynodiol diacetate (100 M + 1.0 ED)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 50 micrograms ethinyl estradiol plus 1.0 mg ethynodiol diacetate (50 EE + 1.0 ED)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol plus 2.0 mg ethynodiol diacetate (30 EE + 2.0 ED)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol plus 0.15 mg levonorgestrel (30 EE + 0.15 NG)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 169

Group type: COMPARATOR
Intervention: Comparative analysis between 50 EE + 1.0 ED and 100 M + 1.0 ED
Number of subjects: 169
Study: 3532141

Group type: EXPERIMENTAL
Intervention: Short leg casting
Number of subjects: 16

Group type: COMPARATOR
Intervention: No short leg casting (uncasted group)
Number of subjects: 16
Study: 30998422

Group type: EXPERIMENTAL
Intervention: Erythromycin (2% w/v) with zinc acetate (1.2% w/v) topical gel
Number of subjects: 102

Group type: COMPARATOR
Intervention: Erythromycin (2% w/v) gel alone
Number of subjects: 102
Study: 29534444

Group type: EXPERIMENTAL
Intervention: Carbohydrate + Protein (CP) during the run (CPDuring)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Carbohydrate + Protein (CP) immediately following exercise (CPPost)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Carbohydrate (CHO) during the run (CHODuring)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Carbohydrate (CHO) immediately following exercise (CHOPost)
Number of subjects: 32
Study: 27549313

Group type: EXPERIMENTAL
Intervention: Balanced anesthesia with sevoflurane for 30 min before removal of the flap and throughout the surgery (BAL group)
Number of subjects: 54
Study: 24411797

Group type: EXPERIMENTAL
Intervention: Drug positive (marijuana and other drugs) among sober drivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug positive (marijuana and other drugs) among drinking drivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other drugs (excluding marijuana)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study: 22744901

Group type: EXPERIMENTAL
Intervention: Robotic assisted vasovasostomy and vasoepididymostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard microsurgical vasovasostomy (MVV) and vasoepididymostomy (MVE)
Number of subjects: 0
Study: 19967408

Group type: EXPERIMENTAL
Intervention: Mutual constructive communication
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mutual avoidance
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Patient demand-partner withdraw communication
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Self‐disclosure
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Holding back
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Partner demand-patient withdraw communication
Number of subjects: 75
Study: 18767584

Group type: EXPERIMENTAL
Intervention: Moxibustion with thunder-fire herbal moxa stick and massage of acupoints and lacrimal gland around the eye
Number of subjects: 70

Group type: COMPARATOR
Intervention: Local dripping Leiran Diyanye
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Moxibustion with thunder-fire herbal moxa stick
Number of subjects: 70
Study: 15869543

Group type: EXPERIMENTAL
Intervention: Myobloc (botulinum toxin type B) 2500 U (0.5 ml) per axilla
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5 ml vehicle (placebo)
Number of subjects: 20
Study: 12672711

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (150 micro g of selenium, 2000 IU of retinol, 120 mg of ascorbic acid, 30 IU of alpha‐tocopherol) with taper training (TT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Taper training (TT)
Number of subjects: 16
Study: 10744143

Group type: EXPERIMENTAL
Intervention: gemfibrozil treatment
Number of subjects: 203
Study: 8808777

Group type: EXPERIMENTAL
Intervention: Combined dipyridamole (150 mg) and aspirin (100 mg) pellet formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional products (dipyridamole and aspirin) given twice daily
Number of subjects: 12
Study: 1422712

Group type: EXPERIMENTAL
Intervention: Colour-coded duplex ultrasonography
Number of subjects: 73
Study: 2413307

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg i.v.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Naloxone (0.4 mg i.v.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg i.v.) plus Naloxone (0.4 mg i.v.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Naloxone (0.4, 2.0, and 8.0 mg i.v.)
Number of subjects: 12
Study: 30452784

Group type: EXPERIMENTAL
Intervention: Fulacimstat 5 mg twice daily (n=9)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fulacimstat 10 mg twice daily (n=9)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fulacimstat 25 mg twice daily (n=10)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fulacimstat 50 mg once daily (n=9)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 39
Study: 29635717

Group type: EXPERIMENTAL
Intervention: Endoscopic screening for esophageal cancer
Number of subjects: 18316

Group type: COMPARATOR
Intervention: Control group (no endoscopic screening)
Number of subjects: 18316
Study: 27717303

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg per day on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo plus letrozole (2.5 mg per day)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 668
Study: 25001077

Group type: EXPERIMENTAL
Intervention: Your Health intervention (consultation with the school nurse)
Number of subjects: 418
Study: 22706884

Group type: EXPERIMENTAL
Intervention: Long-term cancer survivors (LTCSs)
Number of subjects: 2008

Group type: COMPARATOR
Intervention: Cancer-free control group
Number of subjects: 2008
Study: 20559229

Group type: EXPERIMENTAL
Intervention: Local cycloferon liniment in comprehensive treatment of parodontitis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Local cycloferon liniment
Number of subjects: 80
Study: 17589833

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 225 mg
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 15674514

Group type: EXPERIMENTAL
Intervention: Penile block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Caudal block
Number of subjects: 100
Study: 11880017

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study: 11139092

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study: 8784893

Group type: EXPERIMENTAL
Intervention: Intraosseous injection with 1.8 ml of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraosseous injection
Number of subjects: 40
Study: 1461544

Group type: EXPERIMENTAL
Intervention: Nicardipine retard (40 mg twice a day)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice a day)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Nicardipine retard + Hydrochlorothiazide (12.5 mg/day after 2 months if needed)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (12.5 mg/day after 2 months if needed)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Nicardipine retard
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 174
Study: 6597708

Group type: EXPERIMENTAL
Intervention: Lidocaine (40 mg, 2 ml of 2% lidocaine mixed with 50 ml of contrast medium)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lidocaine and Saline (both groups)
Number of subjects: 60
Study: 31502003

Group type: EXPERIMENTAL
Intervention: Fibrinogen/Thrombin-Coated Collagen Patch (TachoSil®)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (no fibrin sealant patch)
Number of subjects: 124
Study: 29661389

Group type: EXPERIMENTAL
Intervention: Esketamine (cumulative dose 40 mg infused in 1 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 12
Study: 29187490

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 30

Group type: COMPARATOR
Intervention: RT
Number of subjects: 30
Study: 26704011

Group type: EXPERIMENTAL
Intervention: Oral 500 ml of 10% glucose solution two hours before surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fasting for 8‐12 hours before operation (Control)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Trial group (Oral carbohydrate) vs Control group (Fasting)
Number of subjects: 35
Study: 24088271

Group type: EXPERIMENTAL
Intervention: IgM-enriched intravenous immunoglobulin (IVIG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both IVIG and placebo
Number of subjects: 38
Study: 21438938

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 3
Study: 18444869

Group type: EXPERIMENTAL
Intervention: Switch arm (half dose of stavudine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuation arm (standard dose of stavudine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 24
Study: 16522418

Group type: EXPERIMENTAL
Intervention: Acupressure at the P6 point
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12657345

Group type: EXPERIMENTAL
Intervention: 1200 mg calcium supplement for 10 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Multivitamin without calcium for 10 days
Number of subjects: 31
Study: 10829467

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9052302

Group type: COMPARATOR
Intervention: PCEA HM 3‐mL (0.15 mg) bolus doses + saline 1 mL IV q6h (Group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: PCEA HM (0.15 mg) in 0.125% bupivacaine 3‐mL bolus doses + saline 1 mL IV q6h (Group 2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PCEA HM 3‐mL (0.15 mg) bolus doses + ketorolac 1 mL (30 mg) IV q6h (Group 3)
Number of subjects: 62
Study: 8379601

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 8
Study: 3518381

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 29676979

Group type: EXPERIMENTAL
Intervention: HP 10 (10% Hydrogen Peroxide)
Number of subjects: 78

Group type: COMPARATOR
Intervention: HP 4 (4% Hydrogen Peroxide)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both HP 4 and HP 10
Number of subjects: 78
Study: 27455158

Group type: EXPERIMENTAL
Intervention: Preoperative chemical thromboprophylaxis (CTP) with 5000 units of subcutaneous heparin
Number of subjects: 376

Group type: COMPARATOR
Intervention: Postoperative chemical thromboprophylaxis (CTP) with 5000 units of subcutaneous heparin
Number of subjects: 376
Study: 25415813

Group type: EXPERIMENTAL
Intervention: PTNS plus tolterodine (4 mg daily for three months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tolterodine alone (4 mg daily for three months)
Number of subjects: 50
Study: 23525434

Group type: EXPERIMENTAL
Intervention: Diesel exhaust inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 0
Study: 20951978

Group type: EXPERIMENTAL
Intervention: High-frequency bilateral subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Off-Stimulation status
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: On-Stimulation conditions
Number of subjects: 10
Study: 19143244

Group type: EXPERIMENTAL
Intervention: Paper splint adduction fixation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Plaster abduction fixation
Number of subjects: 70
Study: 16622748

Group type: EXPERIMENTAL
Intervention: JTE‐522 (tiracoxib) 150 mg once daily for 26 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: JTE‐522 (tiracoxib) 200 mg once daily for 26 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: JTE‐522 (tiracoxib) 150 mg and 200 mg
Number of subjects: 61
Study: 12610786

Group type: EXPERIMENTAL
Intervention: Classroom interventions using Health Promotion/Transtheoretical Model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual classroom education (Control)
Number of subjects: 60
Study: 11199241

Group type: EXPERIMENTAL
Intervention: One-hour educational intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Comparison group (scheduled to receive the intervention later)
Number of subjects: 137
Study: 8810935

Group type: EXPERIMENTAL
Intervention: Regular human insulin 100 U mL‐1 (Actrapid) at a dose of 160 U
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 8
Study: 7917439

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling during hospitalization; at least one of nine counseling procedures related to smoking cessation.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling during hospitalization; more than one counseling procedure.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Information about symptoms of nicotine withdrawal, means of abstaining during hospitalization, means of permanently quitting, or medications for nicotine withdrawal symptoms.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inclusion of smoking cessation in plans for future care upon hospital discharge.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Attitude towards the hospital's nonsmoking policy.
Number of subjects: 43
Study: 2969315

Group type: EXPERIMENTAL
Intervention: cilazapril (mean dose 3.6 +/- 0.9 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 31937274

Group type: EXPERIMENTAL
Intervention: Standardized individual and family‐based suicidal behaviour risk reduction intervention (SPS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Case navigation (NAV)
Number of subjects: 128
Study: 31185955

Group type: EXPERIMENTAL
Intervention: Supervised group exercise two days a week for one hour each (intervention B)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Individual physical exercise minimum two days a week (intervention C)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Treatment as usual (control A)
Number of subjects: 117
Study: 28320793

Group type: EXPERIMENTAL
Intervention: 100 mg berryfruit polyphenolic extract (BFPE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: BFPE vs Placebo
Number of subjects: 28
Study: 26156941

Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK) performed in groups during working hours for 5×10 minutes per week
Number of subjects: 200

Group type: COMPARATOR
Intervention: Home-based physical exercise (HOME) performed during leisure time for 5×10 minutes per week
Number of subjects: 200
Study: 24130356

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 28

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 28
Study: 21455974

Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 65

Group type: COMPARATOR
Intervention: Male participants
Number of subjects: 65
Study: 19583714

Group type: EXPERIMENTAL
Intervention: Vaginal repair with mesh augmentation (mesh group, n = 69)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Traditional anterior and posterior colporrhaphy (no mesh group, n = 70)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both groups (mesh and no mesh)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Vaginal repair with mesh augmentation (mesh group)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Traditional anterior and posterior colporrhaphy (no mesh group)
Number of subjects: 139
Study: 17846310

Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg/d)
Number of subjects: 78
Study: 15535408

Group type: EXPERIMENTAL
Intervention: History of incarceration within 12 months of initiating HAART
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: Higher adherence
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: Time spent in jail among incarcerated subjects
Number of subjects: 1746
Study: 11820338

Group type: EXPERIMENTAL
Intervention: Practice nurse-led coronary preventive care
Number of subjects: 0
Study: 9516068

Group type: EXPERIMENTAL
Intervention: Cognitive status measured by MMSE in patients with cardiovascular complications
Number of subjects: 3111

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption in women
Number of subjects: 3111

Group type: EXPERIMENTAL
Intervention: Treatment of systolic hypertension with calcium antagonists
Number of subjects: 3111

Group type: COMPARATOR
Intervention: Cognitive status measured by MMSE
Number of subjects: 3111
Study: 7759428

Group type: EXPERIMENTAL
Intervention: 6 degrees head-down tilt (HDT) for 10 hours
Number of subjects: 8
Study: 1707109

Group type: EXPERIMENTAL
Intervention: Diltiazem (DZ) pretreatment and infusion (0.12 mg/kg/h for 74 hours starting 2 hours prior to surgery, continued with 90 mg b.i.d. p.o. until day 30)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no diltiazem)
Number of subjects: 134
Study: 290726

Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (50, 100, and 150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (200, 400, and 600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of propoxyphene (50/200, 100/400, and 150/600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (650 mg)
Number of subjects: 0
Study: 31310960

Group type: EXPERIMENTAL
Intervention: Simulated amniotic fluid-like solution (SAFE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 40
Study: 28597355

Group type: EXPERIMENTAL
Intervention: Vesair intravesical balloon
Number of subjects: 75
Study: 26306733

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy protocol (180 min of treatment/day for 10 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy protocol
Number of subjects: 24
Study: 22899425

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for managing dysfunctional thoughts about caregiving and training in self-help techniques
Number of subjects: 125

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 125
Study: 21959255

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 611
Study: 18219701

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study: 16546755

Group type: EXPERIMENTAL
Intervention: Metallothionein-III (MT-III) gene polymorphisms
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Metallothionein-IIA (MT-IIA) promoter region SNPs
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study: 12678210

Group type: EXPERIMENTAL
Intervention: Isoflavone supplements
Number of subjects: 0
Study: 10896637

Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2012777

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 115
Study: 6758757

Group type: EXPERIMENTAL
Intervention: Exposure (behaviorally-focused method)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Applied relaxation (physiologically-focused method)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 34